MED cohort (validation set) | OR (95% CI) | Wald p value | AUC (%) |
---|---|---|---|
(A) | |||
Clinical model | |||
 Age (5-unit increase) | 1.04 (0.65–1.66) | 0.88 |  |
 Gender (male vs. female) | 0.58 (0.10–3.31) | 0.54 | 67 |
 Histology (LUSC/NSCLC NOS vs. LUAD) | 3.88 (0.79–19.18) | 0.1 |  |
miRNA model | |||
 16-miRNA risk score | 1.20 (1.00–1.44) | 0.046 | 76 |
 14-miRNA risk score | 1.37 (1.07–1.75) | 0.013 | 82 |
 4-miRNA risk score | 2.00 (1.17–3.42) | 0.012 | 81 |
(B) | |||
Clinical model | |||
 Age (5-unit increase) | 1.12 (0.67–1.86) | 0.67 |  |
 Gender (male vs. female) | 0.46 (0.07–2.98) | 0.42 |  |
 Histology (LUSC/NSCLC NOS vs. LUAD) | 2.71 (0.51–14.48) | 0.24 | 77 |
 miRNA model | |||
 16-miRNA risk score | 1.19 (0.99–1.45) | 0.07 |  |
(C) | |||
Clinical model | |||
 Age (5-unit increase) | 1.13 (0.67–1.93) | 0.88 |  |
 Gender (male vs. female) | 0.40 (0.06–2.78) | 0.54 |  |
 Histology (LUSC/NSCLC NOS vs. LUAD) | 2.40 (0.42–13.79) | 0.1 | 82 |
 miRNA model | |||
 14-miRNA risk score | 1.37 (1.06–1.77) | 0.018 |  |
(D) | |||
 Clinical model | |||
 Age (5-unit increase) | 1.14 (0.67–1.94) | 0.63 |  |
 Gender (male vs. female) | 0.46 (0.07–3.11) | 0.42 |  |
 Histology (LUSC/NSCLC NOS vs. LUAD) | 1.95 (0.33–11.38) | 0.46 | 80 |
 miRNA model | |||
 4-miRNA risk score | 1.98 (1.11–3.54) | 0.022 |  |